Clinical Trial Snapshot 2016: Novartis Leads On Volume, But Novo Nordisk Posts Highest Success Rate
Executive Summary
Divergence between the companies with the most trials and sponsors with the highest proportion of successful trials is striking in Trialtrove analysis of clinical trials completed in 2016.
You may also be interested in...
Roche Pushes The Boundaries Of Cancer Immunotherapy
Roche is betting that its tumor immunophenotype research can guide combination therapy that will alter the tumor microenvironment, making tumor types than have been resistant to PD-1/L1 inhibitors sensitive to immunotherapy.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.